By Sabela Ojea
Apellis Pharmaceuticals on Tuesday provided an update on the eye-disease drug Syfovre, which has been dogged by safety concerns in recent weeks. Shares of the biopharmaceutical company surged 31%, to $40.35, in after-hours trading.
Write to Sabela Ojea at sabela.ojea@wsj.com
Read the full article here